BACKGROUND: Tumour cells rely on glycolysis and mitochondrial oxidative
Previously, we discovered that coiled-coil helix coiled-coil helix domain-containing protein 4 (CHCHD4) is critical for maintaining intracellular oxygenation and required for the cellular response to hypoxia (low oxygenation) in tumour cells through molecular mechanisms that we do not yet fully understand. Overexpression of CHCHD4 in human cancers, correlates with increased tumour progression and poor patient survival.
RESULTS: Here, we show that elevated CHCHD4 expression provides a proliferative and metabolic advantage to tumour cells in normoxia and hypoxia. Using stable isotope labelling with amino acids in cell culture (SILAC) and analysis of the whole mitochondrial proteome, we show that CHCHD4 dynamically affects the expression of a broad range of mitochondrial respiratory chain subunits from complex I-V, including multiple subunits of complex I (CI) required for complex assembly that are essential for cell survival. We found that loss of CHCHD4 protects tumour cells from respiratory chain inhibition at CI, while elevated CHCHD4 expression in tumour cells leads to significantly increased sensitivity to CI inhibition, in part through the production of mitochondrial reactive oxygen species (ROS). CONCLUSIONS: Our study highlights an important role for CHCHD4 in regulating tumour cell metabolism, and reveals that CHCHD4 confers metabolic vulnerabilities to tumour cells through its control of the mitochondrial respiratory chain and CI biology.
BACKGROUND
Metabolic reprogramming and altered mitochondrial metabolism is a feature of cancer, and thus has become an attractive area for therapeutic exploitation [1, 2] . Given the importance of mitochondria in controlling normal physiological processes, understanding how mitochondrial metabolism underlies tumorigenesis is important for ascertaining its therapeutic potential in cancer.
Previously, we discovered the essential redox-sensitive mitochondrial intermembrane space (IMS) protein CHCHD4, is a critical for regulating intracellular oxygen consumption rate and metabolic responses to low oxygen (hypoxia) in tumour cells [3, 4] . Overexpression of CHCHD4 in human cancers significantly correlates with the hypoxia gene signature, tumour progression, disease recurrence and poor patient survival [3] .
CHCHD4 provides an import and oxidoreductase-mediated protein folding function along with the sulfhydryl oxidase GFER (ALR/Erv1) as a key part of the disulphide relay system (DRS) within the mitochondrial IMS [5] [6] [7] . As such, CHCHD4 controls the import of a number of mitochondrial proteins that contain a twin-CX 9 C or twin-CX 3 C motif [8] [9] [10] .
Additionally, as a component of the DRS, CHCHD4 participates in electron transfer to CIV, the molecular oxygen acceptor of the respiratory chain [11] . We and others have found that the functionally conserved cysteines within the redox sensitive Cys-Pro-Cys (CPC) domain of CHCHD4 regulate its mitochondrial localisation in yeast [12] [13] [14] and human cells [3, 15] .
Recently, we discovered that CHCHD4 regulates intracellular oxygenation in tumour cells, which is dependent on the functionally important cysteines of the CPC motif and CIV activity [4] .
In this study, using both loss-and gain-of-function approaches, we have further explored the mitochondrial mechanism(s) by which CHCHD4 regulates respiratory chain function and tumour cell metabolism.
METHODS
Cell culture. Human osteosarcoma U2OS control and independent clonal cell lines (WT.cl1 and WT.cl3) expressing CHCHD4.1 cDNA (CHCHD4-WT-expressing cells) or CHCHD4-C66A/C668A cDNA (CHCHD4-(C66A/C68A)-expressing cells) have been described by us recently [4] . Human U2OS-HRE-luc [16] or human HCT116 colon carcinoma cells [17] were used to stably express two independent shRNA control vectors (Empty Vector (shRNA control 1) and GFP Vector (shRNA control 2)) or two independent shRNAs targeting CHCHD4 (CHCHD4 shRNA1 or CHCHD4 shRNA2) utilizing a green fluorescent protein (GFP)-SMARTvector TM pre-packaged lentivirus system from ThermoFisher Scientific.
Independent cell lines were selected, expanded and characterized. All cell lines were maintained in Dulbecco's modified eagle medium (DMEM) containing 4.5g/L glucose (#41966-029, Life Technologies), and supplemented with 10% fetal calf serum (#EU-000-F, SeraLabs), 100 IU/mL penicillin/100 μ g/mL streptomycin (#15140-122, Life Technologies) and 6 mM L-glutamine (#25030-024, Life Technologies). Cell lines used were authenticated and routinely confirmed to be negative for any mycoplasma contamination. Hypoxia was achieved by incubating cells in 1% O 2 , 5% CO 2 and 94% N 2 in a Ruskinn SCI-tive workstation, without agitation.
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Antibodies and reagents.
For antibodies, the catalogue number and working dilution used are indicated in brackets. The rabbit polyclonal CHCHD4 (HPA34688, 1:1000) antibody was purchased from Cambridge Biosciences. The mouse monoclonal HIF-1α antibody (#610959, 1:500) was purchased from BD Biosciences. The mouse monoclonal β -actin (ab6276, 1:10000), mouse monoclonal α -Tubulin (ab7291, 1:1000), rabbit polyclonal NDUFS3 (ab110246, 1:500) and rabbit polyclonal UQCRC2 (ab14745, 1:1000) were purchased from
Abcam. The mouse monoclonal anti-myc (9B11 clone, #2276, 1:1000)), rabbit polyclonal PHB1 (#2426, 1:1000), rabbit polyclonal HIF-2α (#7096, 1:1000), rabbit polyclonal AIF were obtained from the National Cancer Centre, Drug Therapeutic Program (NCI-DTP),
Frederick MD and dissolved in dimethyl sulfoxide (DMSO) as we have described previously [16, [18] [19] [20] .
Gene silencing. Non-silencing siRNA duplexes (MISSION® siRNA Universal Negative Control #1, SIC-001) and custom designed siRNA duplexes were purchased from SigmaAldrich, and transfected into subconfluent cells using HiPerfect transfection (QIAGEN) according to the manufacturer's instructions. The target sequences for CHCHD4 were 5'-GAGGAAACGTTGTGAATTA-3' (siRNA1) and 5'-AAGATTTGGACCCTTCCATTC-3' (siRNA2). The target sequences for HIF1A were 5'-TACGTTGTGAGTGGTATTATT-3' (siRNA1) and 5'-TAGAAGGTATGTGGCATTTAT-3' (siRNA2) (Additional file 7 Selection of transduced cell pools carried out by the addition of 0.5 µg/mL puromycin (#P9620, Sigma-Aldrich) to the culture medium, followed by incubation for >96h. Knockdown confirmed by both western blotting for CHCHD4 protein expression and QPCR for CHCHD4 transcript expression.
Gene expression analysis. Total RNA samples were isolated using the GeneElute kit (#RTN350), following the manufacturer's protocol (Sigma-Aldrich). cDNA synthesis was carried out using the qScript synthesis kit (#95048-100), following the manufacturer's protocol (Quantabio). mRNA expression was measured by quantitative (Q)-PCR using SYBR Green Mastermix (#RT-SY2X-NRWOU+B, Eurogentec Ltd.) and the DNA Engine Opticon 2 system (BioRad). The Q-PCR primer sequences are included in Additional file 8.
Mitochondrial copy number. Measurement of mitochondrial (mt)DNA copy number has been described previously [21] . Total DNA samples were isolated using the QIAamp DNA Blood
Mini Kit, following the manufacturer's protocol (Sigma-Aldrich). Relative copy numbers of the single-copy nuclear-encoded gene beta-2-microglobulin (β2M) and the mitochondriallyencoded gene mtND1 were measured by quantitative (Q)-PCR using SYBR Green Mastermix (Eurogentec Ltd.) and the DNA Engine Opticon 2 system (BioRad). The Q-PCR primer sequences are in Additional file 8. To determine the mtDNA content, relative to nuclear DNA, the following equations were used:
Respirometry. Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR)
were determined using a Seahorse XF96 Analyser (Seahorse Bioscience). Respiratory profiles were generated by serial treatment with optimised concentrations of oligomycin (1 µg/mL), p-[trifluoromethoxy]-phenyl-hydrazone (FCCP, 500 nM), and rotenone (500 nM).
Glycolytic profiles were generated by serial treatment of glucose-restricted cells with optimised concentrations of glucose (12.5 mM), oligomycin A (1 μ M,) and 2-DG (50 mM).
Cell number normalisation was carried out post-respirometry using sulforhodamine B (SRB) staining of TCA fixed cells in the assay plate.
Mitochondrial fractionation.
Crude mitochondrial fractions were prepared from cultured cells as follows. All tubes and reagents were pre-chilled, and all steps carried out at 4°C, or on ice.
Cells were collected, and washed twice with homogenisation buffer (HB) (250 mM Mannitol, 5 mM HEPES (pH 7.4), 0.5 mM EGTA, in water). Pellets were resuspended in 1 mL of HB, and transferred to a chilled glass potter. Cells were lysed with 150 strokes of potter on ice, and 50 μ L of homogenate removed for whole cell lysate (WCL) sample. The remaining lysate was spun at 1,000 g for 5 min at 4°C. Supernatants were transferred to fresh tubes, and spun at 2,000 g for 5 min at 4°C. Supernatants were again transferred to fresh tubes, and spun at 10,000 g for 10 min at 4°C. 50 μ L supernatants were retained as the cytoplasm sample.
Mitochondrial pellets were washed with 2-3 mL HB, and spun at 10,000 g for 10 min at 4°C. approximately equal chunks and the proteins reduced, alkylated and digested in-gel. The resulting tryptic peptides were analysed by LC-MSMS using a Q Exactive coupled to an RSLCnano3000 (ThermoFisher Scientific). Raw files were processed using MaxQuant 1.5.2.8 using Andromeda to search a human Uniprot database (downloaded 03/12/14). Acetyl (protein N-terminus), oxidation (M) and deamidation (N/Q) were set as variable modifications and carbamidomethyl (C) as a fixed modification. SILAC data was loaded in R to process it with the Microarray-oriented limma package to call for differential expression [22] , relying on the original normalisation processes produced by MaxQuant as reported previously [23, 24] . Three independent SILAC experiments using control U2OS and calculating the dose at which 50% inhibition of CI activity was achieved. This was calculated as ~500 nM (see Fig. 4a ).
ATP assay. Cellular ATP concentrations were determined using CellTiter-Glo Luminescent Cell Viability Assay reagent and protocol, purchased from Promega (G7570). Briefly, cells
were incubated in parallel in appropriate culture vessels under the conditions and for the duration of time described in the figure legends. Cells were lysed by the addition of a volume of CellTiter-Glo reagent equal to the volume of the culture media, and incubated for 2 min on an orbital shaker at room temperature. 100 µL of each sample was loaded into a 96 well luminometry plate, and the luminescence of each sample was measured using a Tecan Infinite M200 Pro luminescent plate reader. Parallel cell incubations were assayed for relative cell number using the SRB assay, and the luminescence measurements were normalised to the respective SRB measurements.
Live cell imaging. Cells were plated in glass-based black-walled multi-welled microscopy plates, and allowed to adhere overnight. Following treatments (as described in figure legends), plates sealed with air-tight adhesive film, and imaged on a heated stage, using a DMI4000 B inverted microscope (Leica). 
Quantification of western blots (densitometry):
Western blot signal intensity was measured per lane using ImageJ (NIH) analysis software. Sample protein band intensities were normalised to the load control protein β -actin (for whole cell lysates) or PHB1 (for mitochondrial fractions). Relative band intensities were calculated relative to internal control sample.
Statistical analysis: All statistical analyses carried out using Microsoft Excel (2016 edition).
Groups compared using unpaired, two-tailed student's t-test assuming equal variance, with significance set at p<0.05. All error bars represent standard deviation from the mean (SD) except where stated. Sample numbers (n values) and significance marks indicated in figure legends. Area under the curve calculated for each condition or cell line, and significance of difference between groups calculated using student's t-test.
RESULTS

Impact of CHCHD4 on the mitochondrial proteome.
CHCHD4 is responsible for the binding and import of mitochondrial proteins containing a twin CX 9 C or CX 3 C motif including subunits of respiratory chain complexes [8, 10] .
Previously, we demonstrated that CHCHD4 is required for maintaining basal cellular oxygen consumption rate (OCR) [3] and intracellular oxygenation in tumour cells [25] . Recently, we found that loss of CHCHD4 in renal carcinoma cells leads to decreased expression of a range of respiratory chain subunits including NDUFS3 (CI), SDHA (complex II, CII), UQCRC2
(complex III, CIII), and COXIV (CIV) [26] , indicating that CHCHD4 controls the expression of a broader range of respiratory chain subunits than had previously been considered. Thus, we hypothesised that CHCHD4 affects basal cellular OCR and intracellular oxygenation by altering the expression levels of respiratory chain subunits. To investigate the extent to which CHCHD4 affects respiratory chain subunit expression and other mitochondrial proteins, we performed stable isotope labelling with amino acid in cell culture (SILAC) using L-lysine- (Fig. 1c) . We observed respective decreased and increased expression of several known CHCHD4 substrates containing a twin-CX n C motif including COX17, COA6, TIMM8, CHCHD2 and TIMM13 [8, 27] as well as other putative CHCHD4 substrates ( Fig. 1d and which was likely related to the respective differences in significance for CHCHD4 expression in each of these conditions (Table 1) . Importantly, we consistently observed that fold changes of identified proteins in response to loss or gain of CHCHD4 expression were decreased and increased respectively across multiple SILAC experiments (Fig 1 and Table 1 ).
To confirm our SILAC findings, we examined the expression of individual subunits of CI, CII, CIII and CIV in whole cell and enriched mitochondrial fractions by western analyses.
Consistent with our SILAC analyses, we found reduced expression of individual subunits of CI (NDUFS3), CII (SDHA), CIII (UQCRC2) and CIV (COXIV) in enriched mitochondrial fractions isolated from stable CHCHD4 (shRNA) knockdown cells compared to shRNA control cells (Fig. 1f) . Depletion of CHCHD4 using two independent siRNAs similarly reduced the expression of these respiratory chain subunits (Additional file 1b), as we have also shown in our recent study using renal carcinoma cells [28] . Furthermore, consistent with a previous report [29] , we found that loss of CHCHD4 also reduced the expression of AIF Expression of the inner membrane protein prohibitin1 (PHB1) served as a control protein for these experiments as it did not change in response to either CHCHD4 (WT or C66A/C68A) expression or CHCHD4 knockdown ( Fig. 1f-g ). Collectively, our data indicate that CHCHD4
promotes global and dynamic effects on the expression of mitochondrial respiratory chain subunits.
CHCHD4 promotes basal and adaptive metabolic responses, and provides a proliferative advantage to tumour cells.
We have previously reported that overexpression of CHCHD4 in human cancers correlates with hypoxia gene signature, increased tumour progression and metastasis, disease recurrence and poor patient survival [3] . As our SILAC analyses demonstrated significant changes in the expression of respiratory chain subunits, next we assessed the effect of CHCHD4 expression on tumour cell metabolism and growth rate in normoxia and hypoxia. In normoxia, we observed significantly decreased L-lactate levels ( we have shown previously [3] . Alongside this, we observed a corresponding change in the expression of the hypoxia inducible factor (HIF) target lactate dehydrogenase A (LDHA) (Additional file 2b), which converts pyruvate to lactate. Furthermore, we found that elevated CHCHD4 expression led to significantly increased tumour cell growth rate in both normoxia ( 
CHCHD4 confers increased tumour cell sensitivity to CI inhibitors.
Homozygous deletion of chchd4 in mice which is embryonic lethal, results in a decrease in whole CI expression [29] , and human CI deficiency which is fatal, is associated with a cysteine mutation within the CI accessory subunit NDUFB10, which is a CHCHD4 substrate [30] . Our SILAC analyses of CHCHD4 (shRNA) knockdown and shRNA control cells showed a decrease in the expression of a range of CI accessory subunits (Fig. 1a, red dots) .
Conversely, CHCHD4 (WT)-expressing cells compared to control cells showed an increase in the expression of a range of CI subunits including NDUFS3, as well as NDUFA8, NDUFB10, and NDUFB7, which are considered to be CHCHD4 substrates [8, 27] (Fig. 1a, blue dots and Additional file 3). Given this relationship between CHCHD4 and CI biology, we hypothesised that elevated expression of CHCHD4 in tumour cells may render them more sensitive to respiratory chain OXPHOS inhibitors. Indeed, we found that CHCHD4 (WT)-expressing cells were significantly more sensitive to growth inhibition by the CI inhibitor rotenone compared to mutant CHCHD4 (C66A/C68A)-expressing or control cells in normoxia ( Fig. 3a) and hypoxia (Additional file 4a), while there was no significant difference in the effects of sodium azide on growth across cell lines (Fig. 3b and Additional file 4b). As with sodium azide (Additional file 4c), rotenone also blocked HIF-1α protein (Additional file 4d). Together, our data show that the increased sensitivity of CHCHD4 (WT)-expressing cells to growth inhibition is specific to CI inhibition (rotenone) as opposed to CIV inhibition (sodium azide) and occurs irrespective of oxygen levels.
CI is a major source of mitochondrial ROS production, which can have profound effects on cellular viability through oxidative damage to lipids, proteins and nucleic acids [31] .
Therefore next, we assessed mitochondrial ROS (superoxide) production using the ROS reporter MitoSOX. We found that basal ROS levels were similarly low in control and CHCHD4 (WT)-expressing cells (Fig. 3c-e) . However, in response to rotenone, ROS levels were significantly increased in CHCHD4 (WT)-expressing cells compared to control or CHCHD4 (C66A/C68A)-expressing cells (Fig. 3c-d) . Treatment of cells with sodium azide, did not lead to a change in mitochondrial ROS levels (Fig. 3e) . Thus, increased sensitivity of CHCHD4 (WT)-expressing cells to CI inhibition (with rotenone) correlates with increased ROS production in these cells, suggesting that CHCHD4 determines tumour cell sensitivity to oxidative stress.
CHCHD4 promotes mitochondrial ROS production in response to CI inhibition.
To further explore the relationship between CHCHD4 and CI biology, we evaluated the effects of CI inhibition in CHCHD4 (WT)-expressing cells using the small molecule inhibitor BAY 87-2243 [32] . BAY 87-2243 was previously identified from a HIF-reporter screen and was shown to block HIF-1α by targeting CI without inhibiting CIII [32] . BAY 87-2243 exhibits potent antitumor activity in vivo [32] [33] [34] , and has recently been shown to induce mitochondrial ROS through its CI inhibitory activity [35] . As expected, we found that BAY 87-2243 blocked whole CI enzyme activity at doses as low as 5 nM in vitro but was less potent than rotenone (Fig. 4a) . We found that the EC 50 dose (500 nM) of BAY 87-2243 for inhibiting whole CI enzyme activity (Fig. 4a ) also blocked basal OCR by ~50% (Additional file 5a). Consistent with our findings with rotenone ( Fig. 3a) , we found that CHCHD4 (WT)-expressing cells were significantly more sensitive to growth inhibition by BAY 87-2243 treatment compared to control and mutant CHCHD4 (C66A/C68A)-expressing cells in normoxia ( Fig. 4b) and hypoxia (Additional file 5b). Notably, the increased sensitivity of CHCHD4 (WT)-expressing cells to BAY 87-2243 was observed at very low nM doses ( Fig.   4b and Additional file 5b) in normoxia and hypoxia. Moreover, there was no significant change in basal OCR (Additional file 5a) or total cellular ATP levels (Additional file 5c) at these very low nM doses of BAY 87-2243 treatment, suggesting that the effect of CI inhibition on growth inhibition is not mediated by changes at the level of intracellular oxygenation or bioenergetics. Indeed, similar to our findings with rotenone ( Fig. 3c-d) , ROS levels were significantly increased in CHCHD4 (WT)-expressing cells compared to control and CHCHD4 (C66A/C68A)-expressing cells in response to BAY 87-2243 treatment, even at a very low dose of 5 nM (Fig. 4c-d) . The addition of a ROS scavenger, Trolox, significantly reduced ROS levels induced by BAY 87-2243 ( Fig. 4c-d) , and partially rescued the growth inhibitory effect of BAY 87-2243 treatment in CHCHD4 (WT)-expressing cells (Fig. 4e) .
Consistent with these data, we found that CHCHD4 (shRNA) knockdown cells were significantly less sensitive to BAY 87-2243 treatment (Fig. 4f) , when cultured in glucose-free (galactose-containing) media which forces them to utilize the respiratory chain and produce ATP via OXPHOS [36] . Our data indicate that CHCHD4 confers tumour cell sensitivity to mitochondrial ROS produced by CI inhibition.
CHCHD4-mediated HIF-1α induction is blocked by NSC-134754 without affecting the respiratory chain.
Previously, we have shown that CHCHD4 regulates HIF-1α protein induction and HIF signalling in hypoxia, and is required for tumour growth in vivo [3] . Here, we have found that elevated CHCHD4 expression increases tumour cell growth rate ( Fig. 2c and Additional file 2c) and HIF-1α protein levels (Additional file 5c-d) in normoxia and hypoxia. Thus, next we assessed the contribution of HIF signalling to tumour cell growth rate observed in response to elevated CHCHD4 without targeting the respiratory chain. To do this, we used a small molecule HIF pathway inhibitor that we previously identified, named NSC-134754 [16] .
Additional file 6a shows our revised chemical structure for NSC-134754 [20] . NSC-134754
blocks HIF activity in U2OS cells in normoxia and hypoxia within the sub-µM range (IC 50 0.25+0.05 µM). NSC-134754 mediates no direct inhibitory effects on basal OCR (Additional file 6b), does not inhibit whole CI enzyme activity (Fig. 5a) , and does not induce mitochondrial ROS (Fig. 5b) , collectively indicating that NSC-134754 blocks HIF signalling with no respiratory chain involvement. Moreover, in contrast to our growth inhibitor data observed with CI inhibitors (Fig. 3a and Fig. 4b ), we found that NSC-134754 showed a comparable growth inhibitory profile in both control and CHCHD4 (WT)-expressing cells in normoxia and hypoxia ( Fig. 5c-d) . Furthermore, we found that elevated HIF-1α and HIF-2α protein induced in CHCHD4 (WT)-expressing in normoxia and hypoxia was blocked by NSC-134754 ( Fig. 5f and Additional file 6c). Collectively our data show that our small molecule HIF signalling inhibitor, NSC-134754, can significantly block CHCHD4-mediated HIF-α protein induction without affecting the respiratory chain, highlighting the potential for targeting HIF signalling downstream of CHCHD4 and out-with the mitochondrial respiratory chain (Fig. 6) .
DISCUSSION
Tumour cells rely on glycolysis and mitochondrial OXPHOS to survive [1] . Thus, mitochondrial metabolism has become an increasingly attractive area for investigation and therapeutic exploitation in cancer [2] . OXPHOS inhibitors are coming to the forefront for use in specific cancer types [37] . However, given the importance of mitochondrial OXPHOS for controlling intracellular oxygenation required for normal physiological processes, delineating whether or how OXPHOS inhibitors might provide a therapeutic window in cancer is crucially important.
Here we provide evidence that CHCHD4 expression in tumour cells is a critical determinant of the mitochondrial expression of a broad range of respiratory chain subunits including individual subunits of CI, CII, CIII and CIV, some of which are known CHCHD4 substrates (Table 1 , Additional file 3 and [8] ). These CHCHD4-regulated proteins contain both canonical (twin-CX 9 C or CX 3 C) and non-canonical (twin-CX n C) cysteine motifs, suggesting that CHCHD4 is capable of recognising and introducing disulfide bonds into proteins with a more diverse arrangement of cysteines than has previously been described [8] . In addition, we found changes in the mitochondrial expression of proteins previously identified as Mia40 substrates in yeast (e.g. CHCHD1 (Mrp10 in yeast) [38] (Table 1) ).
Importantly, we found that increased expression of CHCHD4 or CHCHD4 knockdown increases or decreases respectively the expression of a number of supernumerary CI subunits involved in CI assembly (Table 1 and Additional file 3, [39]). Our data concur with a previous study showing that targeted deletion of chchd4 in mice results in embryonic lethality by day E8.5, with null embryos displaying severe deficiency in total CI expression, accompanied by less severe defects in total CII-IV expression [29] . Interestingly, we identified at least four accessory CI subunits that are known CHCHD4 substrates (NDUFA8, NDUFB7, NDUFS5 and NDUFB10, CI subunits as well as other respiratory chain complex defects have been observed upon loss or knockdown of apoptosis-inducing factor (AIF) [29, 46] . CHCHD4 has been shown to bind to AIF and is able to restore respiratory function in AIF-deficient cells [29] . Thus, CHCHD4 may also influence whole CI assembly and activity in tumour cells via other proteins involved in DRS function independently of its ability to import CI accessory subunits.
Collectively, our data highlight a fundamental relationship between CHCHD4 function and CI biology. Targeting CI as a therapeutic strategy in cancer has recently garnered considerable interest, due in part to the promising anticancer attributes of the antidiabetic drug metformin and the related biguanidine phenformin [1] . Metformin has been shown to 
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